Table 2 Incidence of CMV infection or... | American Society of Hematology

Table 2

Incidence of CMV infection or disease within 100 days after transplantation

	Placebo, n = 28	Maribavir dose groups*
	Placebo, n = 28	100 mg twice daily, n = 27	400 mg once daily, n = 27	400 mg twice daily, n = 26
CMV infection or disease based on CMV pp65 antigenemia, no. (%)	11 (39)	4 (15) P = .046†	5 (19) P = .116	4 (15) P = .053
CMV infection or disease based on positive plasma CMV DNA PCR, no. (%)	13 (46)	2 (7) P = .001	3 (11) P = .007	5 (19) P = .038
Use of anti-CMV therapy, no. (%)	16 (57)	4 (15) P = .001	8 (30) P = .051	4 (15) P = .002
CMV disease, no. (%)	3 (11)	0 (0) P = .089	0 (0) P = .084	0 (0) P = .091

	Placebo, n = 28	Maribavir dose groups*
	Placebo, n = 28	100 mg twice daily, n = 27	400 mg once daily, n = 27	400 mg twice daily, n = 26
CMV infection or disease based on CMV pp65 antigenemia, no. (%)	11 (39)	4 (15) P = .046†	5 (19) P = .116	4 (15) P = .053
CMV infection or disease based on positive plasma CMV DNA PCR, no. (%)	13 (46)	2 (7) P = .001	3 (11) P = .007	5 (19) P = .038
Use of anti-CMV therapy, no. (%)	16 (57)	4 (15) P = .001	8 (30) P = .051	4 (15) P = .002
CMV disease, no. (%)	3 (11)	0 (0) P = .089	0 (0) P = .084	0 (0) P = .091

Three patients randomized to receive maribavir were excluded from the analysis because they received less than 7 days of study drug due to withdrawal from the study or death and had no virology data after the start of study drug.

†

P values vs placebo as determined by Cochran-Mantel-Haenszel test.

View Large

This Feature Is Available To Subscribers Only